Please assess the completion status of the following clinical trial:

Trial Title: Guanfacine to Improve Substance Use Outcomes in Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 100 treatment seeking women~* Ages 18-70 years~* Body mass index (BMI) of 18-35~* Meet current DSM-V criteria for co-occurring SUDs, with primary DSM-V cocaine or primary DSM-V opioid use disorder AND co-occurring cannabis or alcohol or nicotine use disorders;~* Positive drug urine toxicology screens for primary addictive disorder during a 2-week intake assessment period~* Good health as verified by screening examination~* Able to read English and complete study evaluations~* Able to provide informed written and verbal consent~Exclusion Criteria:~* Meet criteria for physiological dependence on alcohol requiring medical detoxification~* Regular use of anti-hypertensives, anti-arrythmics, antiretroviral medications, and medications that would interact with Guanfacine and be contraindicated as per study physician;~* Psychotic or otherwise severely psychiatrically disabled (i.e., suicidal, homicidal, current mania)~* Significant underlying medical conditions which in the opinion of study physician would preclude patient from fully cooperating or be of potential harm during the course of the study; Specifically hepatic and renal impairment as per liver enzymes at 3X the normal limit, or BUN\>50mg or BUN:Cr \> 10:1.~* Hypotensive women with sitting blood pressure below 100/50 mmHG~* Women who are pregnant, nursing or refuse to use a reliable form of birth control~* EKG evidence at baseline screening of any clinically significant conduction abnormalities, including a Bazlett's QT c\>470 msec for women.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Study Medication (Type: EXPERIMENTAL): guanfacine 3mg/day (GUA)
- placebo (Type: PLACEBO_COMPARATOR): placebo (PBO)

Based on this trial design, predict the completion outcome and termination type (if applicable).